AU Patent

AU2019203002A1 — Nucleoside phosphoramidate prodrugs

Assigned to Gilead Pharmasset LLC · Expires 2019-05-23 · 7y expired

What this patent protects

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following 5 struc…

USPTO Abstract

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following 5 structure: R3b Base R3aN P- 0 0 Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019203002A1
Jurisdiction
AU
Classification
—
Expires
2019-05-23
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Pharmasset LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.